P61 Sustained reduction in confirmed disability progression...

Clinical Neurophysiology 2019 / 08 Vol. 130; Iss. 8

P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

Wolinsky, J.S., Hartung, H.P., Brochet, B., Montalban, X., Naismith, R.T., Manfrini, M., Garas, M., Model, F., Hubeaux, S., Kappos, L., Hauser, S.L.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
130
Language:
english
Journal:
Clinical Neurophysiology
DOI:
10.1016/j.clinph.2019.04.704
Date:
August, 2019
File:
PDF, 47 KB
english, 2019
Conversion to is in progress
Conversion to is failed